Chemotherapy of advanced colorectal carcinoma: Treatment options for elderly patients;Chemotherapie des fortgeschrittenen kolorektalen karzinoms: Behandlungsoptionen für ältere patienten

Onkologie

Volumn 26, Issue SUPPL. 7, 2003, Pages 48-53

  Bokemeyer, C ^a   Honecker, F ^a  

^a Univ Klin Tübingen   (United Kingdom)

Author keywords

Chemotherapy; Colorectal carcinoma; Elderly patients; Irinotecan

Indexed keywords

ALPHA2B INTERFERON; CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; RALTITREXED; TEGAFUR; URACIL;

AGE; AGED; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CARCINOMA; DIARRHEA; HUMAN; META ANALYSIS; NEUTROPENIA; REVIEW; TOXICITY; TREATMENT OUTCOME; TREATMENT PLANNING; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COLORECTAL NEOPLASMS; FLUOROURACIL; GERIATRIC ASSESSMENT; HUMANS; LEUCOVORIN; MIDDLE AGED; NEOPLASM STAGING; PALLIATIVE CARE; TREATMENT OUTCOME;

EID: 0347601932     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000076175     Document Type: Review

References (37)

1. Ries LA, Wingo PA, Miller DS, Howe HL, Weir HK, Rosenberg HM, Vernon SW, Cronin K, Edwards BK: The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer 2000;88:2398-2424.
2. Fentiman IS, Tirelli U, Monfardini S, Schneider M, Festen J, Cognetti F, Aapro MS: Cancer in the elderly: Why so badly treated? Lancet 1990;335:1020-1022.
3. Manton KG, Vaupel JW: Survival after the age of 80 in the United States, Sweden, France, England, and Japan. N Engl J Med 1995;333:1232-1235.
4. Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Albain KS: Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999;341:2061-2067.
5. Balducci L, Corcoran MB: Antineoplastic chemotherapy of the older cancer patient. Hematol Oncol Clin North Am 2000;14:193-212.
6. Honecker F, Kohne CH, Bokemeyer C: Colorectal cancer in the elderly: Is palliative chemotherapy of value? Drugs Aging 2003;20:1-11.
7. Honecker F, Wedding U, Kolb G, Bokemeyer C: Chemotherapy of colorectal cancer - which therapy is justified for elderly patients? Onkologie 2001;24:87-94.
8. Koehne CH, Grothey A, Bokemeyer C, Bontke N, Aapro M: Chemotherapy in elderly patients with colorectal cancer. Ann Oncol 2001;12:435-442.
9. Sargent DJ, Goldberg RM, Jacobson SD, MacDonald JS, Labiancea R, Haller DG, Shepherd LE, Seitz JF, Francini G: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001;345:1091-1096.
10. Balducci L, Extermann M: Management of cancer in the older person: A practical approach. Oncologist 2000;5:224-237.
11. Friedrich C, Pientka, L. Kolb G, Wedding U: Comprehensive geriatric assessment in the elderly cancer patient. Onkologie 2003;26:335-360.
12. Simmonds PC: Palliative chemotherapy for advanced colorectal cancer: Systematic review and meta-analysis. Colorectal Cancer Collaborative Group. Br Med J 2000;321:531-535.
13. Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-1418.
14. Jacobson SD, Cha S, Sargent DJ, O'Connell MJ, Poon M, Buroker T, Kugler J, Goldberg RM: Tolerability, dose intensity, and benefit of 5-FU-based chemotherapy for advanced colorectal cancer (CRC) in the elderly. A North Central Cancer treatment Group (NCCTG) Study. Proc Am Soc Clin Oncol 2001;20:384a (abstract 1534).
15. Koehne CH, Cunningham D, Di CF, Glimelius B, Blijham G, Aranda E, Scheithauer W, Rougier P, Palmer M, Wils J, Baron B, Pignatti F, Schoffski P, Micheel S, Hecker H: Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: Results of a multivariate analysis of 3825 patients. Ann Oncol 2002;13:308-317.
16. Milano G, Etienne MC, Pierrefite V, Barberi-Heyob M, Deporte-Fety R, Renee N: Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 1999;79:627-630.
17. Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ: Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 1995;75:11-17.
18. Cascinu S, Del Ferro E, Catalano G: Toxicity and therapeutic response to chemotherapy in patients aged 70 years or older with advanced cancer. Am J Clin Oncol 1996;19:371-374.
19. Chiara S, Nobile MT, Vincenti M, Lionetto R, Gozza A, Barzacchi MC, Sanguineti O, Repetto L, Rosso R: Advanced colorectal cancer in the elderly: Results of consecutive trials with 5-fluorouracil-based chemotherapy. Cancer Chemother Pharmacol 1998;42:336-340.
20. Popescu RA, Norman A, Ross PJ, Parikh B, Cunningham D: Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 1999;17:2412-2418.
21. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 2001;19:2282-2292.
22. Feliu J, Gonzalez-Baron M, Espinosa E, Garcia-Giron C, de la Gandara I, Espinosa J, Colmenarejo A, Jalon JI, Fernandez Y, de Castro J: Uracil and tegafur modulated with leucovorin: An effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group. Cancer 1997;79:1884-1889.
23. Carmichael J, Popiela T, Radstone D, Falk S, Borner M, Oza A, Skovsgaard T, Munier S, Martin C: Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin-Oncol 2002;20:3617-3627.
24. Douillard J-Y, Hoff P-M, Skillings J-R, Eisenberg P, Davidson N, Harper P, Vincent M-D, Lembersky B-C, Thompson S, Maniero A, Benner S-E: Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002;20:3605-3616.
25. Cassidy J, Twelves C, Van-Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendric J, Maroun J, Marshall J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schilsky R-L: First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002;13:566-575.
26. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000;355:1041-1047.
27. Van Cutsem E, Blijham GH: Irinotecan versus infusional 5-fluorouracil: A phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group. Semin Oncol 1999;26:13-20.
28. Miya T, Goya T, Fujii H, Ohtsu T, Itoh K, Igarashi T, Minami H, Sasaki Y: Factors affecting the pharmacokinetics of CPT11: The body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT11. Invest New Drugs 2001;19:61-67.
29. Rothenberg ML, Cox JV, DeVore RF, Hainsworth JD, Pazdur R, Rivkin SE, Macdonald JS, Geyer CE Jr, Sandbach J, Wolf DL, Mohrland JS, Elfring GL, Miller LL, von-Hoff DD: A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 1999;85:786-795.
30. Van Cutsem E, Dirix L, vam Laethem J, van Belle S, Borner M, Gonzales M, Roth A, Morant R, Mathijs R, Gruia G, Noel N, Bleiberg H: A randomized phase II trial of three different regimens of irinotecan (CPT11): A fixed dose of 350 mg/m2 (A), or an individual dose optimisation (B), or a risk factor optimisation (C) in patients (pts) with metastatic colorectal cancer (MCRC) previously treated with 5-FU. Proc Am Soc Clin Oncol 2000;19:244a (abstract 946).
31. Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR: Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003;21:807-814.
32. de Gramont A, Vignoud J, Tournigand C, Louvet C, Andre T, Varette C, Raymond E, Moreau S, Le Bail N, Krulik M: Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997;33:214-219.
33. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
34. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levi F: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-147.
35. Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E: Clinical pharmacokinetics of oxaliplatin: A critical review. Clin Cancer Res 2000;6:1205-1218.
36. Kouroussis C, Souglakos J, Kakolyris S, Mavroudis D, Malamos N, Kalbakis K, Androulakis N, Agelaki A, Vardakis N, Samonis G, Georgoulias V: Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: A phase II study. Oncology 2001;61:36-41.
37. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.